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Abstract
Background: Gene expression profiling yields quantitative data on gene expression used to create prognostic models that
accurately predict patient outcome in diffuse large B cell lymphoma (DLBCL). Often, data are analyzed with genes classified
by whether they fall above or below the median expression level. We sought to determine whether examining multiple cut-
points might be a more powerful technique to investigate the association of gene expression with outcome.
Methodology/Principal Findings: We explored gene expression profiling data using variable cut-point analysis for 36 genes
with reported prognostic value in DLBCL. We plotted two-group survival logrank test statistics against corresponding cut-
points of the gene expression levels and smooth estimates of the hazard ratio of death versus gene expression levels. To
facilitate comparisons we also standardized the expression of each of the genes by the fraction of patients that would be
identified by any cut-point. A multiple comparison adjusted permutation p-value identified 3 different patterns of
significance: 1) genes with significant cut-point points below the median, whose loss is associated with poor outcome (e.g.
HLA-DR); 2) genes with significant cut-points above the median, whose over-expression is associated with poor outcome
(e.g. CCND2); and 3) genes with significant cut-points on either side of the median, (e.g. extracellular molecules such as
FN1).
Conclusions/Significance: Variable cut-point analysis with permutation p-value calculation can be used to identify
significant genes that would not otherwise be identified with median cut-points and may suggest biological patterns of
gene effects.
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Introduction
Diffuse large B cell lymphoma (DLBCL) is an aggressive disease
witha variable outcome. In order to quantify patientrisk, numerous
biomarkers have been identified that can be detected with a variety
of methods. We recently described the use of a quantitative nuclease
protection assay (qNPA) to measure gene expression levels from
formalin fixed, paraffin embedded (FFPE) tissue blocks of DLBCL
[1]. In a subsequent study of CHOP and rituximab-CHOP (R-
CHOP) treated DLBCL cases, qNPA results for many genes were
significantly associated with overall survival [2]. Initial data analysis
was performed by categorizing patients into expression levels above
and below the median level of expression. The best selected 2-
variable model predicting overall survival in DLBCL was the
combinationofthemajorhistocompatibility(MHC)classIIantigen,
HLA-DRB, and the cell cycle associated gene, MYC. In agreement
with the literature, these results implicated lack of immunosurveil-
lance and increased cell proliferation as important features that
characterize the most aggressive B cell lymphomas [3–8].
We then further explored the relationship between expression
levels and survival for these two genes. We plotted the score test
statistic (logrank test statistic) from Cox regression for the
association of gene expression quantile and survival, where gene
expression was converted to a binary variable with cut-points
defined along a continuous spectrum of low to high expression [9].
For HLA-DRB, the highest logrank statistic chi-square value
indicating the most significant cut-point of gene expression was at
the 20
th percentile. Many other cut-points were also significant [2].
This observation was in keeping with previous data demonstrating
that there is a smooth non-linear association of MHC Class II
expression levels as related to patient risk, with small incremental
decreases in expression corresponding to increases in the hazard
ratio of death with a sharp increase in hazard at lower levels of
expression [10]. For MYC the most significant cut-point was at the
80
th percentile of expression. While the 80
th percentile was the
optimal cut-point, there was a wide range of cut-point values that
were also nominally significant [2]. This has biological implica-
tions for MYC, suggesting that incremental increases in MYC
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22267expression portend a worse prognosis with the sharpest increase in
risk at higher levels of expression.
In the current study, we went on to perform this variable cut-
point analysis on 36 genes to determine whether we could identify
genes that might have significant cut-points other than the median
and how that might be a factor in the reported discrepancies in
prognostic value of genes by different investigators and techniques.
Materials and Methods
Ethics Statement
The project was approved by the University of Arizona
Institutional Review Board (IRB) according to the principles
expressed in the Declaration of Helsinki. The University of
Arizona IRB specifically waived the need for informed consent for
this project.
Patient groups and mRNA data
We used the mRNA levels determined using qNPA (ArrayPla-
te
R Assay, High Throughput Genomics, Tucson, AZ) as described
previously [1,2]. Briefly, unstained FFPE sections of 209 DLBCL,
previously treated with CHOP-like regimens (N=93) or R-CHOP
(N=116) were subjected to the qNPA procedure. This process
begins with cell lysis followed by exposure to specifically designed
probe sets that bind to the target mRNA of interest. S1 nuclease is
used to degrade all single stranded RNA and the surviving probes
are identified by binding to linker probes and detection probes on
the ArrayPlate
R followed by chemiluminescence and imaging. The
study set of cases included FFPE blocks from cases of de novo,
previously untreated DLBCL which had also been a part of 2
larger case series using gene expression profiling of snap frozen
biopsies from patients treated with CHOP or R-CHOP and then
later in a study of ArrayPlate
R gene expression technique on the
corresponding FFPE blocks [2,11,12]. The customized ArrayPla-
te
R assay had been designed to assess the expression levels of 36
prognostic genes identified in DLBCL by different research groups
and published in the literature. A list of the genes, their function (if
known), and the reference from which they were chosen are listed
in Table 1. All research was conducted under an IRB (human
subjects committee) approved protocol from the University of
Arizona. We obtained expression measurements with $95%
success on all but 3 genes, and with #80% success on only one
gene (HTR2B).
Variable cut-point and smooth hazard regression analysis
Variable cut-point (or split-point) analysis was performed on all
36 genes in order to discriminate between groups of patients with
the most significant differences in overall survival. This statistical
technique calculates the score test statistic from a Cox model
(analogous to the logrank statistic) at a continuous spectrum of cut-
points on the gene expression variable [13]. (Typically the
maximum statistic is often used to define best split of patients.)
In the plot (Figure 1), the vertical axis corresponds to the score
statistic on the standard normal scale. To adjust for the evaluation
of the large number of cut-point models, permutation sampling is
used to control the family-wise type 1 error for each gene. The
permutation p-values presented in the cut-point plots are based on
1000 samples, and the horizontal line on each plot corresponds to
the 90
th percentile of the sampled permutation distribution of the
maximum test statistic. Therefore, a cut-point statistical test
reaching above the horizontal line has a permutation adjusted p-
value of ,0.10 [9]. Note that the 90
th percentile horizontal lines
for the genes are at approximately 2.5 for most gene expression
variables; if there were no adjustment for multiple comparisons, a
value of 1.64 would correspond to a p-value of 0.1. Without this
adjustment there would be the tendency to falsely believe
moderately large test statistics correspond to real association,
when observed associations could simply be due to the large
number of cut-point models that have been investigated. In
addition, to control statistical variability, a minimum possible
subgroup size of 10% of total patients was set for each analysis.
Since our previous test of panel-wide interaction between the
CHOP and R-CHOP groups had shown no significance, we
combined the 2 data sets for purposes of the current analysis [2].
However, the cut-point technique adjusted for treatment group
(CHOP versus R-CHOP) as a main effect in the relative risk
regression model, since R-CHOP is well known to be associated
with improved survival. The cut-point technique also allows for
more general adjustment of an existing prognostic model to assess
the statistical significance of the addition of a new gene expression
variable and cut-point. Analyses presented are based on overall
survival, where overall survival is defined as the time from study
registration until death. Patients without an observed death time
are censored at the last known time under follow-up.
While the cut-point evaluation allows the assessment of
statistical significance of multiple partitions of a gene expression
variable, it does not directly lead to an estimate of the underlying
regression function representing how gene expression is associated
with survival. Therefore, we also used hazard regression modeling
(based on a B-spline basis) to calculate smooth estimates of the
hazard function for each gene [14]. An alternative estimation
strategy for smooth hazard regression functions is by local
likelihood [15]. In addition, we transformed each gene expression
variable to be approximately uniformly distributed to make the
analysis consistent with the cut-point analysis, which only depends
on the rank of the gene expression variables. As done for the cut-
point analysis, we adjusted for the two treatment groups (CHOP
versus R-CHOP) via main effect in the relative risk regression
model.
While our combination of cut-point analysis and smooth hazard
regression modeling is useful for interpreting individual effects of a
small set of continuous biological measurements, such as gene
expression with censored survival patient outcome, there are other
related statistical methods available for multivariable modeling
and subgroup analysis. For instance, with respect to smooth
regression modeling, there has been considerable study of
generalized additive models, which consist of additive combina-
tions of smooth univariate regression functions. For deriving
subgroups in the context of many variables, the cut-point methods
we proposed can be utilized recursively to cut-up or partition the
data on multiple covariates to construct regression trees [16].
There is an extenstive discussion of other statistical or machine
learning algorithms in Hastie et al. [17]. Due to the complexity of
some of the multivariable models, their use is often better applied
to patient prognostic predictions or subgroup stratification rather
than probing the interpretation and clinical impact of individual
gene expression measurements. In addition, alternatives to the
smooth hazard regression models based on locally estimated
quantiles of the survival distribution can be helpful for exploring
gene effects [18]; however, we chose the hazard based methods for
our exploration of DLBCL gene expression data given the
relatively modest sample size. In addition, hazard regression
methods tend to achieve better variance control in such cases.
Results
We first generated a series of graphs for each of the 13 genes
with significant logrank statistic (Z-value) (Fig. 1). The different
DLBCL Gene Expression Variable Cut-Point Analysis
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1.
Name in original reference Alternative names qNPA name Reference Function
BCL-6 BCL6* Rosenwald
1/Lossos 6
Transcriptional repressor that controls
germinal center formation [26,27]
IMAGE 1334260 centerin/GCET1 (germinal center
B-cell expressed transcript 1)
SERPINA9* Rosenwald 2 Serpin (serine protease inhibitor) [28]
IMAGE 814622 GCET2 (germinal center B-cell
expressed transcript 2)/HGAL
(human germinal center-
associated lymphoma)
GCET2 Rosenwald 3 Membrane-associated protein with a
putative role in signal transduction [29];
myosin-interacting protein that is a
putative inhibitor of cell migration [30]
HLA-DPa HLA-DPA1 Rosenwald 4 Antigen presentation [31]
HLA-DQa HLA-DQA1 Rosenwald 5 Antigen presentation [31]
HLA-DRa HLA-DRA Rosenwald 6 Antigen presentation [31]
HLA-DRb HLA-DRB* Rosenwald 7 Antigen presentation [31]
alpha-actinin ACTN1* Rosenwald 8 Non-muscle a-actinin isoform involved in
bundling actin filaments and attaching
them to focal adhesions; important for
cell motility [32]
collagen type III alpha1 COL3A1* Rosenwald 9 Type III fibrillar collagen; part of the
extracellular matrix in lymph nodes
[33,34]
connective tissue growth factor CTGF* Rosenwald 10 Heparin and integrin binding protein
involved in extracellular matrix
remodeling [35]
fibronectin FN1* Rosenwald 11/Lossos 5 Extracellular integrin ligand involved in
cell adhesion [36]
KIAA0233 Piezo1 FAM38A Rosenwald 12 Multipass transmembrane protein
involved in mechanotransduction and
regulation of integrin activation [37,38]
urokinase plasminogen
activator
Urokinase/uPA PLAU* Rosenwald 13 Serine protease that activates
plasminogen which results in extracellular
matrix degradation [39]
C-MYC MYC* Rosenwald 14 Transcription factor that controls
proliferation, growth, metabolism,
microRNAs and apoptosis [40]
E21G3 Nucleostemin NS C20orf155 Rosenwald 15 Nucleolar GTP-binding protein that
regulates cell cycle by regulating p53 and
maintains nucleolar structure [41,42]
NPM3 Nucleophosmin 3 NPM3 Rosenwald 16 Nucleolar protein that inhibits ribosome
biogenesis and histone assembly and
enhances transcription [43,44]
BMP6 Bone morphogenetic protein-6 BMP6 Rosenwald 17 Cytokine that regulates B-cell
lymphopoiesis [45]
LMO2 LIM domain only-2 LMO2 Lossos1 Transcription factor that regulates
erythropoiesis and angiogenesis [46,47]
BCL2 BCL2 Lossos 2 Membrane bound protein that prevents
apoptosis [48]
SCYA3 MIP-1a(macrophage inflammatory
protein-1)
CCL3 Lossos 3 Chemokine that recruits cells to sites of
inflammation and inhibits hematopoietic
stem cell proliferation [49]
CCND2 Cyclin D2 CCND2* Lossos 4 Activator of cell cycle progression [50]
DRP2-dystrophin related
protein 2
DRP2 Shipp 1 One of a class of structural proteins that
maintains membrane–associated
complexes at the points of intercellular
contact [51]
PRKACB-protein kinase
C beta 1
PKCbII PRKCB1* Shipp 2 Serine/threonine-specific kinase that
plays a role in B-cell receptor signaling
and B-cell development [52]
H731-nuclear antigen Programmed Cell Death 4 PDCD4* Shipp 3 Protein translation initiation factor
inhibitor that is a putative context-
specific tumor suppressor [53,54]
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along the connected line of chi-square values. The solid horizontal
line represents the 90
th percentile of the permutation distribution
of the maximal score statistics under the assumption the gene is not
associated with patient outcome (i.e., under the null hypothesis).
Given the exploratory nature of this analysis, all values with a
significance cut-off above the 90
th percentile line (type 1 error of
0.10) were considered significant. An overall p-value adjusted for
the permutation analysis is presented on each of the panels. Note
that only score statistics for cut-points that generate subgroups of
patients with $10% of the sample size were considered, since
smaller groups would probably not be considered useful clinically.
We think it is useful to plot the cut-point analysis against the
quantile of the gene expression distribution so that one could just
read what fraction of the sample is above or below the cut-point.
Thirteen out of the 36 genes (36%) had at least 1 significant cut-
point at p,0.10, including SERPINA9, HLA-DRB, ACTN1,
COL3A, CTGF, FN1, PLAU, MYC, BCL6, CCND2, PRKCB1,
PDCD4, and TLE1. Of these, 10 (77%) would have been
significant at a pre-specified cut-point at the median (SERPINA9,
ACTN1, COL3A, CTGF, PLAU, MYC, BCL6, CCND2,
PDCD4, and TLE1) and 3 genes (or a relative 23% of the 13
genes) would not have been significant (HLA-DRB, FN1, and
PRKCB1). Therefore, the median cut-point analysis would have
missed detecting the significance of a notable selection of genes.
Inspection of the graphs revealed patterns that allowed us to
classify the results into 3 different groups. The first group was
defined as those genes with the significant cut-points only below
the median. The second group was defined as genes with
significant cut-points only above the median. The third group
was defined as genes with significant cut-points above, below, or
including the median.
The single gene in the first category was HLA-DRB, with the
highest chi-square values all below the median and the most
significant cut-point at the 20
th percentile. This pattern is
consistent with a gene whose loss is associated with poor outcome.
The two genes that fell into the second category, showing
significant cut-points above the median gene expression values,
were CCND2 and PRKCB1. CCND2 is G1/S-specific regulator
of cyclin-dependent kinases, and PRKCB1 functions as a serine-
and threonine-specific protein kinase. This second pattern is
consistent with genes whose over-expression is associated with
poor outcome.
Ten genes fell into the third category, with significant cut-points
above and below the median gene expression values. The genes in
this category included ACTN1, COL3A, FN1, CTGF, PLAU,
Name in original reference Alternative names qNPA name Reference Function
39 UTR of unknown protein Microtubule-Associated
Protein 1B
MAP1B Shipp 4 Protein that stabilizes microtubules,
attaches other proteins to microtubules
and has a putative role in microvessicle
trafficking [55,56]
Transducin-like enhancer
protein 1
Groucho TLE1* Shipp 5 Transcriptional co-repressor involved in
differentiation of hematopoietic cells
[57,58]
Uncharacterized citrin SLC25A13 Shipp 6 Mitochondrial inner membrane aspartate-
glutamate carrier that moves aspartate to
the cytosol and NADH reducing
equivalents into the mitochondria [59,60]
PDE4B Phosphodiesterase 4B,
cAMP-specific
PDE4B Shipp 7 Phosphodiesterase that degrades cAMP
to inactivate cAMP signaling [61]
Uncharacterized UDP-Gal:betaGlcNAc
b-1,4-galactosyltransferase
polypeptide 1
B4GALT1 Shipp 8 Enzyme that transfers galactose to
glycoproteins in a steriospecific manner;
galactoproteins are involved in immune
cell trafficking [62]
PRKCG Protein kinase C, gamma PRKCG Shipp 9 Serine/threonine–specific kinase
activated by lipid signals and reactive
oxygen species [63,64]
Oviductal glycoprotein MUC9 OVGP1 Shipp 10 Glycoprotein secreted by oviduct
epithelial cells under estrogen control
[65]
(MINO/NOR1) Mitogen induced
nuclear orphan receptor
NR4A3 Shipp 11 Nuclear hormone receptor that regulates
metabolism and inhibits leukemogenesis
in a ligand-independent manner [66,67]
Zinc-finger protein C2H2-150 ZNF212 Shipp 12 Putative transcription factor [68]
5-Hydroxytryptamine 2B receptor HTR2B Shipp 13 Serotonin receptor isotype involved in
tumorigenesis [69,70]
Catalase CAT Tome 1 Peroxisomal enzyme that metabolizes
H2O2 [71]
Manganese superoxide dismutase SOD2 Tome 2 Mitochondrial enzyme that metabolizes
superoxide [72]
1Last names with numbers refer to genes that are members of prognostic gene signatures previously reported in A. Rosenwald et al, I. Lossos et al, M. Shipp et al, and M.
Tome et al. [12], [73], [74], [75].
doi:10.1371/journal.pone.0022267.t001
Table 1.Cont.
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these 10 genes code for extra-cellular molecules. PDCD4 codes for
an apoptosis related molecule, MYC is associated with prolifer-
ation and other cellular processes, while SERPINA9 and BCL6
are related to germinal center formation. While it wasn’t explored
in this analysis, an extended strategy for constructing prognostic
groups of patients with significant cut-points at multiple points in
the gene expression distribution (i.e., above and below the median)
could be implemented. Here, a stage-wise approach would be
appropriate. First, the maximal cut-point with all of the data
would be identified; this defines two subgroups of patients. Next,
evidence of a significant cut-point in either of the two remaining
subgroups would be assessed. As before, permutation resampling
methods would be used to determine evidence of further cut-
points; this would indicate whether more than two prognostic
groups, based on that gene, are needed.
Analysis of the cut-point graphs indicates whether or not
expression of a particular gene is critical for patient outcome.
However, to understand the impact of increasing or decreasing
expression of a particular gene on patient outcome and gain
insight into the tumor biology we generated hazard regression
functions for the 13 genes with significant cut-points (Fig. 2). A
hazard function that is increasing with respect to gene expression
indicates a worse prognosis (or survival) with higher gene
expression; conversely, a decreasing function implies improved
survival for higher gene expression. The hazard regression
functions confirm the importance of these genes and indicate
whether an increase or decrease in expression is associated with
better or worse patient survival. For example, examination of the
hazard regression functions is in agreement with the known data
on MYC. MYC over-expression in DLBCL results from
translocations, increased gene copy number, or other mechanisms,
and correlates with poor patient outcome [19–21].
In secondary analysis, we assessed whether adjustment for the
International Prognostic Index (IPI) [22] mitigated the effect of
gene expression on survival for the 13 genes described above.
Results were similar, with ten of the 13 genes achieving family-wise
error rate of ,0.10.
Discussion
While a large amount of effort in recent years has been devoted
to evaluating thousands of genes from unfixed, snap frozen tissue,
we have focused on a more detailed analysis of a smaller number
of genes using FFPE. In this paper, we investigated the use of
different cut-points for determining gene significance, which we
applied here for the first time on GEP data for 36 genes on
paraffin embedded tissue. We show that while using the median
cut-point is often useful, the significance of some genes may be
missed when the effect is limited to patients with only markedly
high or low (rather than median) levels of expression.
Therefore, we believe the results more generally show that the
variable cut-point method is a powerful tool to explore the
relationship of gene expression data with outcomes. The strategy
produces a sequence of decision rules to directly identify a group of
patients, and hence, has a potential role in the translation of results
to other studies. The second tool, smooth hazard regression, allows
a finer understanding of the underlying biological relationships of
gene expression with patient survival, but doesn’t produce a
decision rule. Therefore, this pair of tools together allows a fuller
interrogation of gene expression data, an approach which has been
largely overlooked under the current paradigm of performing
simple univariate analyses at a genome-wide level. In practice, the
choice of a cut-point derived by the methods we be propose can be
used if there is not a specific cut-point of interest specified based on
prior research. Our proposal would be to evaluate cut-points over
a range of clinical interest. The choice of cut-point for subsequent
clinical applications would often be the one that gave the largest
test statistic value (or smallest p-value). However, one may choose
other significant cut-point values that lead to larger subgroups
depending on the clinical need in future studies. Importantly,
given the multiple possible cut-points evaluated, the methodology
includes an algorithm (permutation resampling) to control for
potential false positive selection of a cut-point; that is, where there
may not be a true association with patient outcome.
While we have focused our analysis and discussion on the
understanding of individual genes, it is important to note that a
cut-point algorithm can also be used to explore and draw
inferences into whether or not other adaptively selected models
might improve the existing prognostic models. Given a model with
a set of specified variables and cut-points, the method allows one to
statistically evaluate all cut-points over all remaining genes to see if
any other variables would improve model performance. We
assessed whether our prior model that included HLA-DRB and
MYC could be improved by applying this method. We found that
inclusion of the gene PDCD4, with a cut-point at the upper 27
th
percentile of its distribution, had an adjusted p-value (controlling
for multiple comparisons) of 0.001 to enter the model. Therefore,
the 3-gene model including HLA-DRB, MYC, and PDCD4
appears to be preferred statistically over the prior 2-gene model.
This improved model would likely not have been evident without
using cut-point methodology.
In this project, a single median cut-point approach would have
missed detecting a notable subset (23%) of the genes that were
most significantly associated with survival at lower or higher
expression cut-points. This may account for differences in
significance of certain genes reported between different studies.
Since a near complete loss of gene expression or high over-
expression may be a relatively infrequent event for certain genes in
some tumor types, these 2 categories of genes may be overlooked
in general data analysis using median cut-points. We note that
both in this data set and others, the statistically significant
association of HLA-DR gene expression with survival would have
been missed if only the median value of expression had been
investigated.
Laboratory methods that either minimize or maximize signal will
tend to underestimate the significance of genes with significant data
c u t - p o i n t sa tl o w e ro rh i g h e rl e v e l so fg e n ee x p r e s s i o n .F o re x a m p l e ,
immunohistochemistry (IHC) often runs the chemical reaction through
to equilibrium and may therefore over-estimate protein expression of
genes by favoring a strong positive reaction. Furthermore, IHC is
usually interpreted with simple descriptions of positive and negative
staining based on visual inspection. Therefore, IHC strongly
Figure 1. Graphs for each of the 13 genes with a significant logrank statistic (Z-value). On the Y-axis, an unadjusted score statistic of 2
corresponds to a p-value of approximately 0.05. On the X-axis, a value of 0.1 corresponds to the 10
th percentile of gene expression, 0.2 to the 20
th
percentile, and etc up to the 90
th percentile of expression. Different cut-point values assessed for each gene are represented by the dots along the
connected line of chi-square values. The solid horizontal line represents the 90
th percentile of the permutation distribution of the maximal score
statistics. The range on the x-axis is from 10% to 90% of the distribution of the gene expression variable. An overall p-value adjusted for the
permutation analysis is shown along the right sided Y-axis.
doi:10.1371/journal.pone.0022267.g001
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amounts of protein. Conversely methods that rely on high amounts of
target for detection may also not reveal genes that are most significant
at low levels of expression. It is therefore apparent that quantitative
data with an appropriate dynamic range will be the most effective for
exploring gene and protein expression patterns that play a prognostic
role in DLBCL and other cancers. This factor might account for some
of the discrepancies seen between gene expression and follow up
confirmatory studies on their protein products.
By grouping similar hazard regression function patterns, we can
speculate about the biological roles of the significant genes in
DLBCL. These groups can differ somewhat from the categories
generated in the cut-point analysis. Genes for which high
expression is correlated with poor survival could be roughly
described as oncogenes. MYC is a charter member of this
category. Inspection of the MYC hazard regression function
indicates that incremental increases have incremental effects on
survival. This category would include CCND2, a protein closely
related to proliferation, which has long been linked to outcome in
DLBCL and mantle cell lymphomas [7,12,23]. PDCD4 also fits
this pattern in DLBCL although studies in other cell types suggest
PDCD4 can play a tumor suppressor role in other contexts [24].
Another hazard ratio pattern could be roughly described as
genes for which loss of expression is associated with poor outcome.
These genes have characteristics of tumor suppressor genes and
include HLA-DRB. The pattern for HLA-DRB, which shows a
sharp increase in hazard at lower levels of expression, also fits our
previous data showing a loss of HLA-DRB is associated with poor
outcome [2]. Previously, we had demonstrated an incrementally
worse overall survival in patients as average major histocompat-
ibility class II (MHC II) gene expression values (of which HLA-
DRB is a principle gene) decreased by quantiles with the poorest
outcome in patients at the 25
th percentile and below [10]. The
current data also agree with our previous analysis that showed a
non-linear association of HLA-DRA (part of the HLA-DR
heterodimer) with patient hazard ratio of death - specifically with
a sharp increase in hazard at lower levels of expression [10]. A
comparison of the hazard regression functions for genes with a less
well understood role in DLBCL to those of MYC and HLA-DRB
provide insight as to their biological significance.
A third hazard ratio pattern is the genes with impact on survival
especially at high and low expression. This pattern is most
pronounced for COL3A1 and FN1, but PLAU also has this
pattern. A gene expression pattern like this argues for threshold
effects rather than a rheostat where incremental increases have
incremental effects on survival. This type of pattern could reflect a
requirement for other proteins in a complex to exert the full
biological effect. Alternatively, this pattern could reflect a different
impact of the gene in subgroups of DLBCL such as the cell of
origin subtypes previously identified by GEP including germinal
center B cell and activated B cell types [11,12,25]. The
information from the hazard regression functions provides the
basis for developing testable hypotheses to determine the
importance of these genes for DLBCL biology.
In summary, we have demonstrated a method of statistical
analysis that can be applied to GEP data and may reveal
interesting associations with patient outcome. In particular, when
data are evaluated by being split at expression levels other than the
median, additional genes that correlate with patient outcome may
be identified. A key component of the analysis is the use of the
appropriate statistical techniques to control for false positive
findings. To this end we have found re-sampling (in this study
permutation sampling) to be extremely useful strategy to avoid
over interpretation of flexible exploratory analysis such as cut-
point techniques. Finally, while these genes and their cut-points
will need to be validated in future studies, the results presented
here may serve as hypothesis generating tools in regards to the use
of particular genes at particular cut-points with possible implica-
tions for gene and tumor biology.
Software implementing the adjusted cut-point analysis is
available from the final author.
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